REG - Futura Medical PLC - Futura Medical - Notice of Interim Results

Futura MedicalAnnouncement

18/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230818:nRSR6806Ja&default-theme=true

RNS Number : 6806J  Futura Medical PLC  18 August 2023

 

18 August 2023

 Futura Medical plc

("Futura" or the "Company")

Notice of Interim Results

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical
company developing innovative sexual health products, will announce its
interim results for the six months ended 30 June 2023 on Monday 18(th)
September 2023.

The Company will host a webcast for investors and analysts on the day of the
results, which will be made available within the investor centre section of
the Company's website.

A Retail Investor event is scheduled for Tuesday 19(th) September at 10.00am
BST with Investor Meet Company. Retail Investors can register
via www.investormeetcompany.com (http://www.investormeetcompany.com/) .

-ENDS-

For further information, please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Nick Bastin/ Jonathan Edwards/ Zoe Bolt/ Elena Bates

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

 

About Futura Medical plc

 

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing
innovative products based on its proprietary, transdermal
DermaSys® technology.

MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED")
has a unique evaporative mode of action and is clinically proven as an
effective topical treatment for adult men with ED, with a key claim of
"Helps you get an erection within 10 minutes". Eroxon® is available Over the
Counter ("OTC") without a doctor's prescription. www.eroxon.com
(http://www.eroxon.com) .

MED3000 is being manufactured and commercialised under the brand name Eroxon®
in regulatory approved countries and is FDA approved in the US, CE marked
in Europe and UKCA marked in the UK and a growing number of countries
across the world. Futura has commercial agreements with the likes of Haleon
for the US market and Cooper Consumer Health for Europe.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUBUUROBUWAAR